BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 8563470)

  • 1. Dominant negative and DNA-binding properties of mutant thyroid hormone receptors that are defective in homodimerization but not heterodimerization.
    Kitajima K; Nagaya T; Jameson JL
    Thyroid; 1995 Oct; 5(5):343-53. PubMed ID: 8563470
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The function of retinoid X receptors on negative thyroid hormone response elements.
    Takeda T; Nagasawa T; Miyamoto T; Hashizume K; DeGroot LJ
    Mol Cell Endocrinol; 1997 Apr; 128(1-2):85-96. PubMed ID: 9140079
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative analysis of DNA binding affinity and dimerization properties of wild-type and mutant thyroid hormone receptor beta1.
    Takeda T; Nagasawa T; Miyamoto T; Minemura K; Hashizume K; Degroot LJ
    Thyroid; 2000 Jan; 10(1):11-8. PubMed ID: 10691308
    [TBL] [Abstract][Full Text] [Related]  

  • 4. N-terminal variants of thyroid hormone receptor beta: differential function and potential contribution to syndrome of resistance to thyroid hormone.
    Ng L; Forrest D; Haugen BR; Wood WM; Curran T
    Mol Endocrinol; 1995 Sep; 9(9):1202-13. PubMed ID: 7491112
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Functional properties of a mutant T3 receptor beta (R338W) identified in a subject with pituitary resistance to thyroid hormone.
    Sasaki S; Nakamura H; Tagami T; Miyoshi Y; Nakao K
    Mol Cell Endocrinol; 1995 Aug; 113(1):109-17. PubMed ID: 8674808
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Spectrum of transcriptional, dimerization, and dominant negative properties of twenty different mutant thyroid hormone beta-receptors in thyroid hormone resistance syndrome.
    Collingwood TN; Adams M; Tone Y; Chatterjee VK
    Mol Endocrinol; 1994 Sep; 8(9):1262-77. PubMed ID: 7838159
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Isoform variable action among thyroid hormone receptor mutants provides insight into pituitary resistance to thyroid hormone.
    Safer JD; Langlois MF; Cohen R; Monden T; John-Hope D; Madura J; Hollenberg AN; Wondisford FE
    Mol Endocrinol; 1997 Jan; 11(1):16-26. PubMed ID: 8994184
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural features of thyroid hormone response elements that increase susceptibility to inhibition by an RTH mutant thyroid hormone receptor.
    Zavacki AM; Harney JW; Brent GA; Larsen PR
    Endocrinology; 1996 Jul; 137(7):2833-41. PubMed ID: 8770904
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amino acid substitutions of thyroid hormone receptor-beta at codon 435 with resistance to thyroid hormone selectively alter homodimer formation.
    Nomura Y; Nagaya T; Tsukaguchi H; Takamatsu J; Seo H
    Endocrinology; 1996 Oct; 137(10):4082-6. PubMed ID: 8828460
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Resistance to thyroid hormone caused by two mutant thyroid hormone receptors beta, R243Q and R243W, with marked impairment of function that cannot be explained by altered in vitro 3,5,3'-triiodothyroinine binding affinity.
    Yagi H; Pohlenz J; Hayashi Y; Sakurai A; Refetoff S
    J Clin Endocrinol Metab; 1997 May; 82(5):1608-14. PubMed ID: 9141558
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dominant negative inhibition by mutant thyroid hormone receptors is thyroid hormone response element and receptor isoform specific.
    Zavacki AM; Harney JW; Brent GA; Larsen PR
    Mol Endocrinol; 1993 Oct; 7(10):1319-30. PubMed ID: 8264663
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nuclear corepressors enhance the dominant negative activity of mutant receptors that cause resistance to thyroid hormone.
    Tagami T; Jameson JL
    Endocrinology; 1998 Feb; 139(2):640-50. PubMed ID: 9449636
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cell type-dependent modulation of the dominant negative action of human mutant thyroid hormone beta 1 receptors.
    Wong R; Zhu XG; Pineda MA; Cheng SY; Weintraub BD
    Mol Med; 1995 Mar; 1(3):306-19. PubMed ID: 8529109
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interaction of human beta 1 thyroid hormone receptor and its mutants with DNA and retinoid X receptor beta. T3 response element-dependent dominant negative potency.
    Meier CA; Parkison C; Chen A; Ashizawa K; Meier-Heusler SC; Muchmore P; Cheng SY; Weintraub BD
    J Clin Invest; 1993 Oct; 92(4):1986-93. PubMed ID: 8408652
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Understanding the molecular mechanism of dominant negative action of mutant thyroid hormone beta 1-receptors: the important role of the wild-type/mutant receptor heterodimer.
    Zhu XG; Yu CL; McPhie P; Wong R; Cheng SY
    Endocrinology; 1996 Feb; 137(2):712-21. PubMed ID: 8593822
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thyroid hormone resistance syndrome: correlation of dominant negative activity and location of mutations.
    Nagaya T; Eberhardt NL; Jameson JL
    J Clin Endocrinol Metab; 1993 Oct; 77(4):982-90. PubMed ID: 8408475
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DNA binding affinity of hTRbeta1 mutants as heterodimers with traps from different tissues.
    Takeda T; Suzuki S; Nagasawa T; Liu RT; DeGroot LJ
    Biochimie; 1999 Apr; 81(4):297-308. PubMed ID: 10401662
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential sensitivity of thyroid hormone receptor isoform homodimers and mutant heterodimers to hormone-induced dissociation from deoxyribonucleic acid: its role in dominant negative action.
    Zhu XG; McPhie P; Cheng SY
    Endocrinology; 1997 Apr; 138(4):1456-63. PubMed ID: 9075702
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thyroid hormone receptor-beta mutants associated with generalized resistance to thyroid hormone show defects in their ligand-sensitive repression function.
    Piedrafita FJ; Ortiz MA; Pfahl M
    Mol Endocrinol; 1995 Nov; 9(11):1533-48. PubMed ID: 8584031
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dominant negative activity of mutant thyroid hormone alpha1 receptors from patients with hepatocellular carcinoma.
    Lin KH; Zhu XG; Hsu HC; Chen SL; Shieh HY; Chen ST; McPhie P; Cheng SY
    Endocrinology; 1997 Dec; 138(12):5308-15. PubMed ID: 9389515
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.